Word

ZORYA

Status

Pending

Status Code

686

Status Date

Tuesday, June 11, 2024

Serial Number

79371681

Mark Type

4

Filing Date

Wednesday, December 7, 2022

Published for Opposition

Tuesday, June 11, 2024

Trademark Owner History

CYTOO - Owner At Publication

Classifications

9 Quality control and testing devices namely culture plates to test and conduct quality control in the field of biology, biotechnology and pharmacy; downloadable software for the collection, processing and analysis of data in the field of biotechnology and pharmacy; scientific laboratory instruments, namely computer hardware and downloadable software for data analysis, database management, data processing, in the field of life science research and the pharmaceutical industry market and diagnostics

5 Pharmaceutical products, namely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; Veterinary products, namely veterinary preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; Sanitary products for medicine, namely sanitary preparations for medical use; Chemical and biological preparations for medical use, namely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity , diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; chemical and biological preparations for pharmaceutical use for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases

42 Medical, biotechnological, and pharmaceutical research; research and development of chemical, biological and scientific products and materials in the biological, biotechnological, medical, diagnostic and pharmaceutical fields; scientific research, advisory and information services in the medical, biotechnological, pharmaceutical, diagnostic, technological and industrial fields; design and development of computers, software and computer platforms; technical testing namely technological testing in the scientific, biological, biotechnological and medical fields and quality control services of goods and services; advisory services with respect to quality testing, technical testing namely, technological testing in the scientific, biological, biotechnological and medical fields and scientific and medical clinical trials; services for scientific development and analysis of cell tests; scientific and medical research and development of products and services in the field of imaging, in the scientific, biological, biochemical, molecular-biology, biotechnological and medical fields; Scientific interpretation and analysis of data by imaging in the scientific, biological, biochemical, molecular-biology, biotechnological and medical fields; diagnostic and industrial research in the biological, biotechnological and medical fields

The wording "ZORYA" has no meaning in a foreign language.

Trademark Events

Jun 8, 2023

Sn Assigned For Sect 66a Appl From Ib

Jun 12, 2023

New Application Office Supplied Data Entered

Jun 16, 2023

Application Filing Receipt Mailed

Sep 13, 2023

Assigned To Examiner

Sep 24, 2023

Non-Final Action Written

Sep 25, 2023

Non-Final Action (Ib Refusal) Prepared For Review

Oct 4, 2023

Refusal Processed By Mpu

Oct 4, 2023

Non-Final Action Mailed - Refusal Sent To Ib

Oct 25, 2023

Refusal Processed By Ib

Apr 4, 2024

Teas Response To Office Action Received

Apr 4, 2024

Correspondence Received In Law Office

Apr 6, 2024

Teas/Email Correspondence Entered

May 6, 2024

Examiners Amendment -Written

May 6, 2024

Examiners Amendment E-Mailed

May 6, 2024

Notification Of Examiners Amendment E-Mailed

May 6, 2024

Examiner's Amendment Entered

May 6, 2024

Approved For Pub - Principal Register

May 12, 2024

Teas Change Of Owner Address Received

May 12, 2024

Attorney/Dom.Rep.Revoked And/Or Appointed

May 12, 2024

Teas Change Of Correspondence Received

May 12, 2024

Applicant/Correspondence Changes (Non-Responsive) Entered

May 12, 2024

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

May 22, 2024

Notification Of Notice Of Publication E-Mailed

Jun 11, 2024

Published For Opposition

Jun 11, 2024

Official Gazette Publication Confirmation E-Mailed